Drug intelligence / Profile preview

lapathoside A

Development stage: Preclinical
Lead developer: Jeju National University
Modality: Small Molecules
Administration: Parenteral

Overview

Lapathoside A is a phenylpropanoid ester isolated from the roots of buckwheat (*Fagopyrum esculentum*). It has been investigated for its potential anticancer properties, particularly against human pancreatic cancer cell lines such as PANC-1 and SNU-213. Research indicates that lapathoside A significantly reduces cell viability and induces apoptosis in these cell lines by modulating the expression levels of apoptotic proteins. The compound was identified through solvent partitioning and liquid chromatography of buckwheat root extracts, and its structure was confirmed using mass spectrometry and nuclear magnetic resonance analysis. It is currently in the preclinical research stage for the treatment of pancreatic cancer.

Other names: lapathoside A

Beyond the preview

Go deeper on lapathoside A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lapathoside A.

Explore the full profile